Form: 8-K

Current report filing

April 13, 2010

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES AND EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): April 9, 2010

 

 

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

601 Biotech Drive

Richmond, Virginia 23235
(Address of principal executive offices)

Registrant’s telephone number, including area code: (804) 648-3820

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.

On April 9, 2010, the Nasdaq Stock Market (“NASDAQ”) filed a Form 25 with the Securities and Exchange Commission to complete the delisting of the Registrant’s common stock. As previously reported, trading of the Registrant’s common stock was suspended on January 22, 2010 for failure to meet the minimum stockholders’ equity requirement under NASDAQ Listing Rule 5550(b), and has not traded on NASDAQ since that time. The delisting will become effective ten days after the filing of the Form 25. The Registrant’s common stock has traded on the OTC Bulletin Board since March 25, 2010.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.
By:  

/s/ Richard J. Freer, Ph.D.
  Richard J. Freer, Ph.D.
  Chief Operating Officer

Dated: April 13, 2010